Compounds > tributyrin
Page last updated: 2024-08-17

tributyrin and Cancer of Colon

tributyrin has been researched along with Cancer of Colon in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Oliveira, TF; Furtado, KS; Heidor, R; Miranda, ML; Moreno, FS; Ortega, JF; Purgatto, E; Tavares, PE; Vieira, A1
Le Maux, S; Li, Y; McClements, DJ; Xiao, H1
Hong, SS; Kang, SN; Lee, MK; Lim, SJ1
Clarke, KO; Feinman, R; Harrison, LE1
Maurer, HR; Schröder, CP1
Deschner, EE; Lupton, JR; Newmark, HL; Ruperto, JF1

Other Studies

6 other study(ies) available for tributyrin and Cancer of Colon

ArticleYear
The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage.
    Toxicology and applied pharmacology, 2014, Apr-15, Volume: 276, Issue:2

    Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Apoptosis; Colonic Neoplasms; Deoxyguanosine; DNA Damage; Histone Deacetylase Inhibitors; Male; Precancerous Conditions; Rats; Rats, Wistar; Triglycerides; Weight Gain

2014
Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent.
    Journal of agricultural and food chemistry, 2009, Oct-14, Volume: 57, Issue:19

    Topics: Anticarcinogenic Agents; Colonic Neoplasms; Corn Oil; Drug Delivery Systems; Drug Stability; Emulsions; HT29 Cells; Humans; Solubility; Triglycerides

2009
Dual function of tributyrin emulsion: solubilization and enhancement of anticancer effect of celecoxib.
    International journal of pharmaceutics, 2012, May-30, Volume: 428, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Carriers; Drug Synergism; Emulsions; HCT116 Cells; Humans; Melanoma; Mice; Oils; Particle Size; Prodrugs; Pyrazoles; Solubility; Sulfonamides; Surface-Active Agents; Triglycerides

2012
Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3.
    Cancer letters, 2001, Sep-28, Volume: 171, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Butyrates; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Colonic Neoplasms; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA-Binding Proteins; E2F Transcription Factors; E2F4 Transcription Factor; Enzyme Activation; G1 Phase; Neoplasm Proteins; Nuclear Proteins; Phenotype; Phenylbutyrates; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Transcription Factors; Triglycerides; Tumor Cells, Cultured

2001
Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro.
    International journal of oncology, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Alkaline Phosphatase; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Differentiation; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Humans; Triglycerides; Tumor Cells, Cultured

2002
Dietary butyrate (tributyrin) does not enhance AOM-induced colon tumorigenesis.
    Cancer letters, 1990, Jun-30, Volume: 52, Issue:1

    Topics: Animals; Azo Compounds; Azoxymethane; Body Weight; Cocarcinogenesis; Colonic Neoplasms; Diet; Drug Evaluation, Preclinical; Fatty Acids; Feces; Female; Mice; Precancerous Conditions; Triglycerides

1990